117 related articles for article (PubMed ID: 33413292)
21. Case Report: Systemic Treatment and Serial Genomic Sequencing of Metastatic Prostate Adenocarcinoma Progressing to Small Cell Carcinoma.
Lu X; Gao W; Zhang Y; Wang T; Gao H; Chen Q; Shi X; Lian B; Zhang W; Gao X; Li J
Front Oncol; 2021; 11():732071. PubMed ID: 34646773
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of dermatomyositis associated with adenocarcinoma of the prostate after radical prostatectomy.
Masuda H; Urushibara M; Kihara K
J Urol; 2003 Mar; 169(3):1084. PubMed ID: 12576853
[No Abstract] [Full Text] [Related]
23. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
24. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
[No Abstract] [Full Text] [Related]
25. Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy.
Tállai B; Flaskó T; György T; Ponyi A; András C; Tóth C; Dankó K
Clin Rheumatol; 2006 Feb; 25(1):119-20. PubMed ID: 16132164
[TBL] [Abstract][Full Text] [Related]
26. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
27. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
29. Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis.
Malangone-Monaco E; Foley K; Varker H; Wilson KL; McKenzie S; Ellis L
Clin Ther; 2016 Aug; 38(8):1817-24. PubMed ID: 27491282
[TBL] [Abstract][Full Text] [Related]
30. Dermatomyositis and esophageal cancer.
Iftikhar I; Abdelmannan D; Daw HA
South Med J; 2006 Jul; 99(7):777-9. PubMed ID: 16866067
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
[TBL] [Abstract][Full Text] [Related]
32. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
[TBL] [Abstract][Full Text] [Related]
33. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
[TBL] [Abstract][Full Text] [Related]
34. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Morris MJ; Rumble RB; Basch E; Hotte SJ; Loblaw A; Rathkopf D; Celano P; Bangs R; Milowsky MI
J Clin Oncol; 2018 May; 36(15):1521-1539. PubMed ID: 29608397
[TBL] [Abstract][Full Text] [Related]
35. Dermatomyositis and malignant effusions: rare manifestations of carcinoma of the prostate.
Rapoport AH; Omenn GS
J Urol; 1968 Aug; 100(2):183-7. PubMed ID: 5658662
[No Abstract] [Full Text] [Related]
36. [Dermatomyositis associated with carcinoma of the prostate and esophagus].
Bessonov IA
Vrach Delo; 1971 Dec; 12():99-101. PubMed ID: 5137887
[No Abstract] [Full Text] [Related]
37. Large-cell neuroendocrine carcinoma of prostate. Case report.
Moratalla Charcos LM; Pastor Navarro T; Cortes Vizcaino V; Osca Garcia JM; Gil Salom M
Arch Esp Urol; 2013 May; 66(4):368-71. PubMed ID: 23676541
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
[TBL] [Abstract][Full Text] [Related]
39. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
Culine S; El Demery M; Lamy PJ; Iborra F; Avancès C; Pinguet F
J Urol; 2007 Sep; 178(3 Pt 1):844-8; discussion 848. PubMed ID: 17631339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
